Santen Pharmaceutical Co., Ltd. (TSE:4536) Not Lagging Market On Growth Or Pricing

With a price-to-earnings (or “P/E”) ratio of 17.2x Santen Pharmaceutical Co., Ltd. (TSE:4536) may be sending bearish signals at the moment, given that almost half of all companies in Japan have P/E ratios under 12x and even P/E’s lower than 8x are not unusual. Although, it’s not wise to just take the P/E at face value as there may be an explanation why it’s as high as it is.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Recent times haven’t been advantageous for Santen Pharmaceutical as its earnings have been rising slower than most other companies. One possibility is that the P/E is high because investors think this lacklustre earnings performance will improve markedly. If not, then existing shareholders may be very nervous about the viability of the share price.

Check out our latest analysis for Santen Pharmaceutical

Keen to find out how analysts think Santen Pharmaceutical’s future stacks up against the industry? In that case, our free report is a great place to start.

What Are Growth Metrics Telling Us About The High P/E?

There’s an inherent assumption that a company should outperform the market for P/E ratios like Santen Pharmaceutical’s to be considered reasonable.

Retrospectively, the last year delivered a decent 3.8% gain to the company’s bottom line. This was backed up an excellent period prior to see EPS up by 546% in total over the last three years. Therefore, it’s fair to say the earnings growth recently has been superb for the company.

Shifting to the future, estimates from the eight analysts covering the company suggest earnings should grow by 13% per year over the next three years. That’s shaping up to be materially higher than the 9.7% per year growth forecast for the broader market.

With this information, we can see why Santen Pharmaceutical is trading at such a high P/E compared to the market. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

The Bottom Line On Santen Pharmaceutical’s P/E

We’d say the price-to-earnings ratio’s power isn’t primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

As we suspected, our examination of Santen Pharmaceutical’s analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. At this stage investors feel the potential for a deterioration in earnings isn’t great enough to justify a lower P/E ratio. It’s hard to see the share price falling strongly in the near future under these circumstances.

Before you take the next step, you should know about the 1 warning sign for Santen Pharmaceutical that we have uncovered.

Of course, you might also be able to find a better stock than Santen Pharmaceutical. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.